ripekg:evaluation/RIPEA7A26A29DA8B9E483 |
prov:wasInformedBy |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
rdf:type |
rdfs:Resource |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
rdf:type |
owl:Thing |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
rdf:type |
ripe:EvidenceAggregationEvidence aggregation |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
rdf:type |
tido:Activity |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
prov:startedAtTime |
2025-11-04T19:01:50.831053Z |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA7A26A29DA8B9E483 |
ripekg:publication-details/RIPEA7A26A29DA8B9E483Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
ripekg:registry-evidence/RIPEA7A26A29DA8B9E483 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |
ripekg:study-design-evidence/RIPEA7A26A29DA8B9E483 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA7A26A29DA8B9E483 |